Key Events This Week
1 June: Q4 FY26 results reveal exceptional income masking operational weakness
1 June: MarketsMOJO upgrades rating to Sell on improved technicals and valuation
5 June: Stock rallies 3.11% on strong volume, closing at Rs.35.52
Jun 24, 11:20 AM
BSE+NSE Vol: 10.0 k

Biofil Chemicals & Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 17 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.
Read full news article
1 June: Q4 FY26 results reveal exceptional income masking operational weakness
1 June: MarketsMOJO upgrades rating to Sell on improved technicals and valuation
5 June: Stock rallies 3.11% on strong volume, closing at Rs.35.52
Biofil Chemicals & Pharmaceuticals Ltd's latest financial results for Q4 FY26 reveal a complex picture of operational performance. The company reported net sales of ₹7.57 crores, reflecting a significant quarter-on-quarter growth of 780.23% from the previous quarter's ₹0.86 crores. However, this surge is contrasted by a year-on-year decline of 9.34%, indicating ongoing demand challenges despite the apparent recovery. Net profit for the quarter stood at ₹0.21 crores, which is a 162.50% increase compared to the previous quarter, and a 5.00% increase year-on-year. While this uptick in profit may seem positive, it is essential to note that the overall operational performance remains inconsistent. The operating margin decreased to 5.68% from 11.63% in the prior quarter, suggesting rising input costs or unfavorable product mix despite higher sales. The volatility in revenue is a critical concern, with sales flu...
Read full news article
Biofil Chemicals & Pharmaceuticals Ltd., a micro-cap pharmaceutical company with a market capitalisation of ₹57.00 crores, reported net profit of ₹0.21 crores in Q4 FY26 (Mar'26), marking a modest 5.00% increase year-on-year but a substantial 162.50% surge quarter-on-quarter. However, this apparent profitability improvement conceals deeper operational challenges, as the company's core business performance remains under significant pressure with volatile revenue patterns and contracting margins.
Read full news article
Biofil Chemicals & Pharmaceuticals Ltd has seen its investment rating upgraded from Strong Sell to Sell, reflecting a nuanced shift in its technical outlook and valuation metrics despite ongoing fundamental challenges. The upgrade, effective from 29 May 2026, is driven primarily by improved technical indicators and a more attractive valuation grade, while financial trends and quality scores remain subdued.
Read full news article
25 May: Stock dips 0.92% to Rs.31.16 despite Sensex rally
26 May: Upper circuit hit with 19.99% gain, closing at Rs.37.09
27 May: Downgrade to Strong Sell announced amid mixed technicals
29 May: Week closes at Rs.35.11, down 3.14% on final trading day

Biofil Chemicals & Pharmaceuticals Ltd has seen its investment rating upgraded from Sell to Strong Sell, driven primarily by shifts in technical indicators and valuation metrics. Despite persistent challenges in financial trends and quality fundamentals, the recent market performance and valuation adjustments have prompted this reassessment, signalling cautious investor sentiment amid mixed signals.
Read full news article
Biofil Chemicals & Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from a very attractive to an attractive rating, despite a challenging performance relative to the broader market. This change, driven primarily by adjustments in its price-to-earnings and price-to-book ratios, offers investors a fresh perspective on the stock’s price attractiveness within the Pharmaceuticals & Biotechnology sector.
Read full news article
At Rs 37.82, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Biofil Chemicals & Pharmaceuticals Ltd locked at its upper circuit of 19.99% on 26 May 2026, with buyers queuing and no sellers willing to part with shares.
Read full news articleSubmission of publication of Audited Financial Results in the Newspaper pursuant to Regulation 47 of SEBI (Listing Obligation and Disclosure Requirement) Regulations 2015
Audited Financial Result for the Financial Year ended 31.03.2026
Outcome of Board Meeting held on Saturday 30th May 2026 pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available